Selexis empowers scientists and biopharmaceutical companies around the world to realize the full potential of their work.
With more than 95 partners worldwide, nearly 80 drug candidates in clinical manufacturing, and two commercial products, SUREtechnology has a history of empowering scientists and biopharmaceutical companies around the world to realize the full potential of their research, helping them reach patients with new treatments faster.
RECENT AND UPCOMING EVENTS
October 31-November 4, 2016
PEGS Europe | Lisbon, Portugal > Speaking, Corporate Sponsor and Exhibitor
Wednesday, November 2 at 12:30 PM “Engineering CHO Cell Lines for Enhanced Robustness”
November 7-9, 2016
BIO Europe | Cologne, Germany > Partnering
Selexis will be participating in partnering meeting.
January 9-13, 2017
PepTalk | San Diego, USA
January 9-13, 2017
J.P. Morgan Healthcare Conference | San Francisco, USA
“Selexis is continually optimizing its proprietary cell line and technology platform to enable partners such as Amgen to make better R&D decisions by generating reliable data points faster and more cost efficiently.”
“Faron expects that the agreement with Selexis will serve to significantly improve the chances of success and to accelerate this value realization for Faron stakeholders.”
“I’m really proud of what we did over the last 15 years to retranslate basic gene expression technologies into a unique toolset used by nearly 90 leading companies worldwide, and, at the same time, we were able to help develop over 70 candidate products that are now in the clinics.”
“The productivity and speed of stable cell line generation with the SUREtechnology Platform™ is playing a key role in quickly progressing our candidate into clinical development.”
“We are a pioneering life sciences company that offers cell line development technologies in order to assist in the development and translation of new therapies into products. We are the only company that can consistently produce any difficult-to-express protein that our partners need.”
“Making world-class biologics more affordable just got easier through the partnership of JHL Biotech and Selexis.”
“We chose Selexis based on its track record for overcoming expression bottlenecks with difficult-to-express proteins and generating fully documented cell lines used for clinical manufacturing.”
“Selexis licenses the biopharmaceutical industry a refined protein expression engine –a regulatory and industry-validated engineered cell line that allows for rapid speed in the production of recombinant drugs.”